Log in to search using one of your social media accounts:

 

Girl With Rare Disease Races Time Via Virtual Tech
Pediatric brain disease patients the latest to gather data for clinical trials from the comfort of their own home. (Source: WebMD Health)
Source: WebMD Health - April 23, 2018 Category: Consumer Health News Source Type: news

Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: a phase 3 randomized trial - Bisaga A, Mannelli P, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Sullivan MA.
BACKGROUND: Injectable extended-release naltrexone (XR-NTX), approved to prevent relapse to opioid dependence, requires initial abstinence. This multisite outpatient clinical trial examined the efficacy and safety of low-dose oral naltrexone (NTX), combine... (Source: SafetyLit)
Source: SafetyLit - April 23, 2018 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Efficacy of botox versus placebo for treatment of patients with major depression - Zamanian A, Jolfaei AGHANBARI, Mehran G, Azizian Z.
BACKGROUND: Treatment of major depression is crucial to decrease the burden of disease. Hence, in this study, the efficacy of Botox was compared with placebo for treatment of patients with major depression.METHODS: In this randomized clinical trial... (Source: SafetyLit)
Source: SafetyLit - April 23, 2018 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

The effect of tai chi exercise on the risk and fear of falling in older adults: a randomized clinical trial - Mortazavi H, Tabatabaeichehr M, Golestani A, Armat MR, Yousefi MR.
BACKGROUND: Falling and fear of falling are among the most common problems of the elderly, which can cause illness, isolation, dependency and reduced quality of life in elderly. Exercise is recommended to prevent falling injuries in the elderly. AI... (Source: SafetyLit)
Source: SafetyLit - April 23, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

FDA approves Medtronic ’ s drug-coated balloon to treat long superficial femoral artery lesions
The FDA approved Medtronic‘s (NYSE:MDT) In.Pact Admiral drug-coated balloon to treat long superficial femoral artery lesions up to 360mm in patients with peripheral artery disease, the medtech giant touted today. In a 227-patient global trial, participants treated with Medtronic’s drug-device combination therapy had a one-year patency rate of 89.1% and a clinically-driven target revascularization rate of 7.1%. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves Medtronic’s drug-coated balloon to treat long superficial femoral artery lesions appeared first on MassDevic...
Source: Mass Device - April 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Vascular Wall Street Beat Medtronic Source Type: news

Woodford-backed biotech Prothena plunges as key drug fails
LONDON (Reuters) - Shares in Prothena, a biotech company backed by British investor Neil Woodford, plunged 70 percent on Monday after its main drug for treating a rare disease called AL amyloidosis failed in a crucial clinical trial. (Source: Reuters: Health)
Source: Reuters: Health - April 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Bringing innovation to clinical trial design
Clinical trials are critical to the discovery and development of innovative medicines that enable patients to live longer, healthier lives. As the biopharmaceutical industry works to identify, test and bring new medicines to patients, clinical trials are instrumental in determining the safety and efficacy of a potential new treatment.  (Source: The Catalyst)
Source: The Catalyst - April 23, 2018 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Tags: Research and Development Clinical Trials Source Type: news

UTHealth receives funding to study stem cell therapy for traumatic injury
(University of Texas Health Science Center at Houston) The University of Texas Health Science Center at Houston (UTHealth) has received funding through a public/private partnership for the first-ever clinical trial investigating a stem cell therapy for early treatment and prevention of complications after severe traumatic injury. The proposed Phase 2 trial is underwritten with $2 million from the Medical Technology Consortium (MTEC) and $1.5 million from Memorial Hermann Foundation. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 23, 2018 Category: Biology Source Type: news

IBS patients obtain robust, enduring relief from home-based treatment program
(University at Buffalo) In the largest federally funded non-drug clinical trial for irritable bowel syndrome (IBS), patients with the most severe and persistent symptoms achieved robust and sustained relief by learning to control symptoms with minimal clinician contact. Led by University at Buffalo researchers in collaboration with colleagues at New York University and Northwestern University, the study was published online before print in Gastroenterology. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 23, 2018 Category: International Medicine & Public Health Source Type: news

Glenmark clinical trial in Jaipur dragged into controversy, CDSCO to probe allegations
The issue has escalated to a point where even the Central Drugs Standard Control Organisation, India's apex drug regulatory body, has sent inspectors to probe the matter. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 22, 2018 Category: Pharmaceuticals Source Type: news

Neurosurgeon Eric Leuthardt: ‘An interface between mind and machine will happen’
The US researcher – and sci-fi author – on how brain implants will drive the next turning point in human evolutionDr Eric C Leuthardt, 45, is a neurosurgeon at Washington University in St Louis. He is also the co-founder of NeuroLutions, a research laboratory developing directinterfaces between mind and computer. Leuthardt is pioneering the use of electrical brain implants to help restore motor function to the paralysed limbs of stroke victims. He is also helping to develop electrode systems that can directly decode the unspoken “inner voice” of the mind, and use it to direct external action; for ex...
Source: Guardian Unlimited Science - April 21, 2018 Category: Science Authors: Tim Adams Tags: Neuroscience Medical research Ethics Health Technology Biology Source Type: news

Injectible drug shown to be effective against lupus in clinical trial
Injections of the drug Belimumab, marketed as Benlysta, benefited patients with a form of lupus in a Phase 3 clinical trial, researchers reported this week. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 20, 2018 Category: Consumer Health News Source Type: news

FDA Approves First Drug for Rare Form of Rickets
FRIDAY, April 20, 2018 -- Ultragenyx Pharmaceutical Inc.'s Crysvita (burosumab-twza) has been approved by the U.S. Food and Drug Administration to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH). A clinical trial... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 20, 2018 Category: Pharmaceuticals Source Type: news

FDA approves IDE trial for Urotronic ’s drug-coated balloon
Minneapolis-based Urotronic said this week that the FDA approved an investigational device exemption trial for its Optilume drug-coated balloon catheter, which is designed to treat urethral strictures in men. The 200-patient pivotal trial is slated to start enrolling participants immediately. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves IDE trial for Urotronic’s drug-coated balloon appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 20, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Urology Vascular urotronic Source Type: news

Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional)
Funding to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). (Source: PHPartners.org)
Source: PHPartners.org - April 20, 2018 Category: International Medicine & Public Health Source Type: news

Hologic touts study comparing NovaSure to Minerva ’ s endometrial ablation device
Hologic (NSDQ:HOLX) yesterday released results from a study comparing its NovaSure endometrial ablation system to Minerva Surgical‘s endometrial ablation device, touting a higher one-year rate of amenorrhea and higher quality of life for women treated with the NovaSure , despite experiencing a higher rate of perioperative adverse events. Results from the trial were published in the International Journal of Women’s Health, Marlborough, Mass.-based Hologic said. In the 189-patient study, researchers compared the use of endometrial ablation with either the NovaSure or Minerva device. The study’s primary...
Source: Mass Device - April 20, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Women's Health Source Type: news

Nasal spray of party drug shows promise as fast-acting antidepressant, researchers say
The latest clinical trial of esketamine, the nasal-spray form of the club drug ketamine, is boosting confidence among some psychiatrists that it could be a major advance in the treatment of suicidal depression. In a study published this week in the American Journal of Psychiatry, researchers report that an esketamine trial resulted in a “rapid improvement in depressive symptoms” […]Related:E. coli outbreak spreads as source of tainted lettuce remains a mysteryFirst marijuana-derived drug poised for FDA approval after winning support from advisersNew CDC chief stepped down from four gr...
Source: Washington Post: To Your Health - April 20, 2018 Category: Consumer Health News Source Type: news

Germany's Merck seeks partners for cancer and immune system drugs
FRANKFURT (Reuters) - Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D. (Source: Reuters: Health)
Source: Reuters: Health - April 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Rwanda:Health Ministry to Increase Clinical Trials
[New Times] The Ministry of Health, through Rwanda Biomedical Centre (RBC), is committed to expand the scope of evidence-based healthcare by conducting more clinical trials, officials have said. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 20, 2018 Category: African Health Source Type: news

Lupus treatment generates positive results in Phase III clinical trial
(Wiley) New research indicates that belimumab, a monoclonal antibody therapy that targets a component of the immune system, provides considerable benefits to patients with systemic lupus erythematosus (SLE), a predominately female, chronic inflammatory disease that can affect virtually any organ. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 20, 2018 Category: International Medicine & Public Health Source Type: news

PMG Research Recognized for Excellence in Vaccine Study Execution
PMG Research today announced that it has been awarded Best Clinical Trial Site Network at the Vaccine Industry Excellence (ViE) Awards.(PRWeb April 20, 2018)Read the full story at http://www.prweb.com/releases/2018/04/prweb15425295.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 20, 2018 Category: Pharmaceuticals Source Type: news

Argos discontinues troubled trial, delists from Nasdaq
Argos made a series of announcements Thursday that reflect troubles stemming from a challenging 2017. The company has said it will discontinue its lead clinical trial, move from the Nasdaq to an OTC market and has hired a financial advisor to help consider its alternatives. Argos (Nasdaq: ARGS) disclosed Thursday that – based on new interim results – it decided to discontinue its phase 3 ADAPT trial of Rocapuldencel-T for the treatment of metastatic kidney cancer and has notified the U.S. Food… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 19, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

OncoBreak: Clinical Trial Barriers; Healthy Cancer Patients; Marriage and Melanoma
(MedPage Today) -- News, features, and commentary about cancer-related issues (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 19, 2018 Category: American Health Source Type: news

Emboline, Inc. Completes Funding Of Over $10 Million
Combination of $3 Million in Equity Financing and Conversion of $7 Million in Convertible Notes will Fund Clinical Trial for the Emboliner™ Embolic Protection Catheter SANTA CRUZ, Calif., April 19, 2018 -- (Healthcare Sales & Marketing Network) -- Embo... Devices, Interventional, Cardiology, Venture Capital Emboline, Emboliner, Embolic Protection, TAVR (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 19, 2018 Category: Pharmaceuticals Source Type: news

Emboline raises $10m Series B for TAVR embolism filter
Emboline said today that it pulled in a $10 million Series B round for the namesake embolic protector it’s developing for heart valve replacement procedures. The Emboliner catheter is designed to prevent blood clots from passing into the cerebral vasculature during transcatheter aortic valve replacements. Santa Cruz, Calif.-based Emboline said the round includes $3 million from a consortium led by SV Tech Ventures and Shangbay Capital and $7 million in already-issued convertible notes. The cash is earmarked for Emboline’s SafePass clinical trial, submission for CE Mark approval and initial commerciali...
Source: Mass Device - April 19, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Replacement Heart Valves Vascular Wall Street Beat Emboline Source Type: news

OBV/PTV/r+DSV+RBV in Patients With HCV Cirrhosis OBV/PTV/r+DSV+RBV in Patients With HCV Cirrhosis
Does real-life data confirm the results of clinical trials regarding the efficacy and safety profile of this DAA regimen in patients with HCV infection and cirrhosis?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 19, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Clinical trial tests tattoo sensor as needleless glucose monitor for diabetes patients
(University of California - San Diego) A phase I clinical trial at UC San Diego Health is testing the accuracy of a needleless glucose monitor that adheres to the skin like a temporary tattoo to read blood sugar levels. The sensor was developed by University of California San Diego Jacobs School of Engineering researchers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 19, 2018 Category: International Medicine & Public Health Source Type: news

Researchers use imaging technology to screen for colorectal cancer in young adults
(Boston Medical Center) Researchers at Boston Medical Center, in collaboration with Northwestern University, are using imaging technology to create an effective and inexpensive way to screen for colorectal cancer among young adults. The research is part of the R33 Cancer Moonshot Project, and is a 3 year $1.5 million grant from the National Cancer Institute. Once researchers create this test and achieve quality goals, they will begin a clinical trial, which can then lead to regulatory approval and launch in clinical practice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 19, 2018 Category: Cancer & Oncology Source Type: news

Pregnant Women in Clinical Trials: A Better Mix Than You'd Think
(MedPage Today) -- More research on pregnant and lactating women is needed, says NIH official (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 18, 2018 Category: American Health Source Type: news

CardioFocus raises $13m
CardioFocus has raised $13 million in a new round of mixed financing, according to an SEC filing posted this week. Money in the round comes from a single unknown investor, according to the filing, with the first sale noted as having occurred on April 4. The Marlborough, Mass.-based company said that $2.6 million from the offering will go towards sales commissions and finders fees, according to the filing. CardioFocus is seeking an additional $8 million before closing the offering, bringing the total it hopes to raise up to $21 million. In February, CardioFocus said that it launched a clinical trial for the latest iteration...
Source: Mass Device - April 18, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Wall Street Beat CardioFocus Inc. Source Type: news

2 Bay Area drug approvals in 1 day underscore industry's issues, opportunities
Pricing and the wear and tear of years of clinical trials remain issues for the drug-development industry. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 18, 2018 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Tetherex Pharmaceuticals, Inc. Completes $50M Series B Financing
Funding to support Phase 2 clinical trials of the company's PSGL-1 inhibitor, SelK2, in multiple indications OKLAHOMA CITY, April 18, 2018 -- (Healthcare Sales & Marketing Network) -- Tetherex Pharmaceuticals, Inc., a privately held biopharmaceutical c... Biopharmaceuticals, Venture Capital Tetherex Pharmaceuticals, venous thromboembolism, PSGL-1, SelK2 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 18, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves First Contact Lens That Gets Darker In Sunlight
CBS Local — The U.S. Food and Drug Administration has approved a new invention that may make wearing sunglasses a thing of the past. FDA officials signed off on the first ever transition contact lenses, which will get darker when the wearer is out in sunlight. “This contact lens is the first of its kind to incorporate the same technology that is used in eyeglasses that automatically darken in the sun,” the FDA’s Malvina Eydelman said in a press release. The agency tested the new lenses on 24 patients to make sure there were no problems with driving during the day and at night. None of the users repo...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 17, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Chris Melore Contact Lenses FDA Local TV Sunglasses talkers Source Type: news

vTv Therapeutics plans to keep its High Point headquarters despite building sale, clinical setback
vTv Therapeutics plans to keep its headquarters at its current location in High Point despite the building being purchased by a new owner and plans to end clinical trials for an Alzheimer's drug it has been developing, the company confirmed Tuesday. The prospect of vTv Therapeutics moving its office from 4170 Mendenhall Oaks Parkway was raised after it was revealed Cambrex Corp. bought the 40,000-square-foot structure, along with its own building, for $10.2 million on April 6. The revelations… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 17, 2018 Category: Biotechnology Authors: Jessica Seaman Source Type: news

vTv Therapeutics plans to keep its High Point headquarters despite building sale, clinical setback
vTv Therapeutics plans to keep its headquarters at its current location in High Point despite the building being purchased by a new owner and plans to end clinical trials for an Alzheimer's drug it has been developing, the company confirmed Tuesday. The prospect of vTv Therapeutics moving its office from 4170 Mendenhall Oaks Parkway was raised after it was revealed Cambrex Corp. bought the 40,000-square-foot structure, along with its own building, for $10.2 million on April 6. The revelations… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 17, 2018 Category: American Health Authors: Jessica Seaman Source Type: news

Drug Active in RET-Altered Tumors (CME/CE)
(MedPage Today) -- Objective response rate of 40%-50% in preliminary clinical trial (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 17, 2018 Category: Hematology Source Type: news

Clinical Trials Need to be More Inclusive, Experts Say
(MedPage Today) -- Children, seniors, and chronic disease patients need more options (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 17, 2018 Category: American Health Source Type: news

CROs form alliance to focus on pediatric drug studies
Exton-based KinderPharm and WorldWide Clinical Trials Inc. said Tuesday they have entered into an alliance to create what they are described as "the world's first center of excellence for pediatric drug development and clinical research" for the pharmaceutical industry. Financial terms of the partnership are being kept confidential. Officials from the two contract research organization noted about 60 percent of drugs prescribed for children are not approved for pediatric use because the drugs were… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 17, 2018 Category: Biotechnology Authors: John George Source Type: news

CROs form alliance to focus on pediatric drug studies
Exton-based KinderPharm and WorldWide Clinical Trials Inc. said Tuesday they have entered into an alliance to create what they are described as "the world's first center of excellence for pediatric drug development and clinical research" for the pharmaceutical industry. Financial terms of the partnership are being kept confidential. Officials from the two contract research organization noted about 60 percent of drugs prescribed for children are not approved for pediatric use because the drugs were… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 17, 2018 Category: Health Management Authors: John George Source Type: news

Coordinating Center to Support NIDA Rural Opioid HIV and Comorbidity Initiative (U24 - Clinical Trial Not Allowed)
The purpose of this FOA is to fund a single interdisciplinary Coordinating Center to formalize and centralize support of the rural opioid initiative administered by NIDA and co-funded by CDC, SAMHSA, and ARC. (Source: HSR Information Central)
Source: HSR Information Central - April 17, 2018 Category: International Medicine & Public Health Source Type: news

Bioelectronic Medicine: Targeting Inflammatory Disease with Electricity
We presented positive initial results in Crohn’s disease at the 2016 United European Gastroenterology meeting: six of the eight patients had seen a substantial reduction in their disease activity index scores, and three were in remission from the disease. As SetPoint looks ahead, several chronic disease areas are emerging as key bioelectronic medicine therapy targets, and our company is exploring a number of these. One of our preclinical programs explores bioelectronic medicine’s potential role as a treatment for MS.   New Target: Multiple Sclerosis In late 2017, SetPoint presented positive data from a s...
Source: Mass Device - April 17, 2018 Category: Medical Devices Authors: Anthony Arnold Tags: Bioelectronic Medicine Clinical Trials Neuromodulation/Neurostimulation SetPoint Medical Sponsored Content Source Type: news

FDA enhances the transparency of clinical trials
Ashton Steinhagen, lead clinical research associate, IMARC When the FDA reviews a new drug application (NDA), they typically review multiple data sets, summaries, and other reports provided by the Sponsor. However, the amount of information that is usually released by the FDA at the time of approval was limited at best as well as sporadic.  Under the FDA’s Clinical Data Summary Pilot Program, transparency of the approval process and access to more study-related documents are the goals, according to FDA commissioner Scott Gottlieb, M.D. who released a statement on 16 January 2018 about the new pilot program. In t...
Source: Mass Device - April 17, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog IMARC Source Type: news

Latest Mesothelioma Immunotherapy Combination Looks Promising
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - April 17, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Novocure touts top-line data from Ph2 mesothelioma trial
Novocure (NSDQ:NVCR) today touted positive top-line data from its Phase II pilot mesothelioma trial and revealed that it plans to submit a humanitarian device exemption application to the FDA for approval. The St. Helier, N.J.-based company reported that patients who received treatment with its “Tumor Treating Fields” system plus chemotherapy experienced clinically meaningful improvements in overall survival and progression-free survival compared to historical control data. Get the full story at our sister site, Drug Delivery Business News. The post Novocure touts top-line data from Ph2 mesothelioma trial ...
Source: Mass Device - April 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat NovoCure Source Type: news

Morris Animal Foundation awards $775K to test osteosarcoma immunotherapy vaccine in dogs
(Morris Animal Foundation) Morris Animal Foundation has awarded a $775,000 grant to the University of Pennsylvania to test a vaccine that could improve longevity and quality of life for dogs with the deadly bone tumor, osteosarcoma. The research team will conduct clinical trials to evaluate a novel immunotherapy treatment which combines a molecule expressed by cancer cells with a modified live form of the bacteria Listeria monocytogenes. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 17, 2018 Category: Biology Source Type: news

Can a simple blood test rule out lung cancer?
(Medical University of South Carolina) A blood test to measure the levels of two proteins in plasma that are common predictors of lung cancer was 98 percent effective in a multicenter clinical trial at distinguishing benign from malignant lung nodules when combined with a patient's clinical characteristics to form an integrated classifier. These results were reported by a team of investigators at the Medical University of South Carolina in an article in Chest. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 17, 2018 Category: International Medicine & Public Health Source Type: news

Nuvo launches pivotal trial for PregSense home maternity monitor
Pregnancy care device developer Nuvo Group said late last week it launched a trial of its PregSense maternal fetal monitoring system to compare it against cardiotocography, which is currently the standard of care. The Israel-based company’s PregSense device is a sensor-based wearable monitoring technology designed to measure markers of fetal and maternal wellbeing from metrics including fetal movements, fetal heart rate, maternal heart rate and uterine activity through the use of surface electrodes. The 200-patient trial is slated to be conducted across four international sites, with a primary endpoint of assess...
Source: Mass Device - April 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Women's Health nuvogroup Source Type: news

Pa., N.J. health systems and universities form multistate clinical trials consortium
Thomas Jefferson and Drexel universities, Main Line Health at the Einstein Healthcare Network are among the members of the "independent and co-managed" nonprofit consortium. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 16, 2018 Category: Biotechnology Authors: John George Source Type: news

Pa., N.J. health systems and universities form multistate clinical trials consortium
Thomas Jefferson and Drexel universities, Main Line Health at the Einstein Healthcare Network are among the members of the "independent and co-managed" nonprofit consortium. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 16, 2018 Category: Health Management Authors: John George Source Type: news

Ivantis touts 1-year head-to-head Hydrus, iStent study data
This study looks at the viability of MIGS in patients who don’t need or may have already had cataract surgery, so it’s a vital addition to our growing body of evidence supporting MIGS,” Compare trial medical monitor Dr. Iqbal Ahmed said in a prepared release. Ivantis said the 152-patient trial was the first to compare two minimally invasive glaucoma surgery device for treating open-angle glaucoma in a standalone procedure. The study aimed to compare safety and effectiveness of both devices in lowering IOP and reducing eye-drop medication. Results at one year showed that 47% of eyes treated with the Hydrus...
Source: Mass Device - April 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Ivantis Source Type: news